Nebulisers for the elderly J C Pounsford Asthma mortality in England and Wales is the Hodgkinson's mini mental test, 5 was the best predictor of inability to use a metered dose slowly rising with about 2000 deaths per annum.
1 If these figures are examined with inhaler. In a further study a breath activated and metered dose inhaler was shown to be the respect to age, corrected for population size, mortality in patients over the age of 65 is rising only inhaler that some patients with moderately severe memory loss could use. 6 As 20% of significantly and deaths in those aged over 80 is increasing exponentially.
1 Some "asthma patients over the age of 80 are significantly cognitively impaired, assessment of cognitive deaths" may be explained by changing patterns in death certification with chronic obstructive function becomes an important aspect in the management of patients in whom inhaled therpulmonary disease (COPD) being certified as asthma. There is a need to ensure that older apy is being considered. For patients who are cognitively impaired a nebulised bronchopatients are diagnosed accurately and treated in the most appropriate manner.
dilator would seem a useful option, but a well trained carer might be able to administer Nebulisers in the elderly are largely used to administer inhaled bronchodilators to patients bronchodilators satisfactorily with a metered dose inhaler and a spacer or a dry powder with bronchial asthma and COPD with reversibility. There is a lack of published data on inhaler.
The relative paucity of evidence to show the efficacy and use of nebulisers in this age group, and clinical decisions tend to be based that nebulisers are better than metered dose inhalers, particularly when used in high dose on results from studies in younger patients. Some studies in COPD have included patients with spacers, necessitates all types of metered dose inhalers and dry powder inhalers being up to the age of 75 but the results have rarely been examined with respect to age. available and considered for each patient. The only inhaler device which has been shown to This paper will consider some of the special features of asthma in the elderly which might give a significant benefit to the elderly and patients with poor inhaler technique is the modify nebuliser use. In addition, some of the risks of high dose agonists and anticholinergic Autohaler. 7 8 Many patients inhale well from the Autohaler but they have considerable drugs will be discussed. difficulty in spring loading the device. In a number of uncontrolled studies the Turbohaler is popular with patients although elderly Use of metered dose inhalers patients frequently complain that they are unOne of the most challenging problems in man-aware whether they are receiving the drug when aging elderly patients with asthma is the de-they inhale from the device. The risk of inhalalivery of treatment to the lungs. Armitage and tion from an empty Turbohaler is not inWilliams 2 showed that age was a major factor considerable. when assessing whether patients were able to Having exhausted trials of various inhaler use a metered dose inhaler correctly, with devices including instructing patients and, if patients under the age of 65 doing significantly necessary, carers on the use of large spacer better than older patients. The older patients devices, a nebuliser needs to be considered if were significantly less likely to learn an inhaler patients are not adequately treated. Special technique than the younger patients. The study consideration must be given to the drugs and also showed that many metered dose inhalers the dosage that are conventionally used in currently available in the UK require con-nebulisers. siderable strength in the index finger and thumb to activate aerosol release. The force required could not be achieved by a large proportion of elderly patients studied. Buckley 3 assessed agonists The incidence of ischaemic heart disease rises inhaler technique in relation to age in patients with asthma and COPD. Those with COPD with age and this may be asymptomatic. Care should be exercised when administering a were older and less likely to be able to use an inhaler correctly than asthmatic patients, but nebulised agonist to a patient with known ischaemic heart disease and the first dose age was not an independent factor in predicting inability to use an inhaler.
should be given in the lung function laboratory, ideally with an ECG recording before drug Age and strength might predict problems with competence in inhaler technique in the administration. The incidence of dysrrhythmias following nebulised agonists is well general asthmatic population, but in an elderly cohort of patients age becomes much less im-recognised 9 10 and has been reported to be as
S54
Pounsford convalescent phase of their illness, but the the return to baseline FEV 1 following methacholine challenge and subsequent agonist risk of a serious dysrrhythmia was significantly increased in those who had had a previous administration is considerably impaired in elderly patients with asthma compared with myocardial infarction. 9 
Hypokalaemia
11 is a recognised complication younger patients. This evidence, and the relative lack of side of nebulised agonist therapy and baseline potassium levels should be measured, par-effects from inhaled anticholinergics, suggests that anticholinergic drugs should always be ticularly if patients are on a diuretic or have a poor dietary intake. The combination of theo-considered in a nebuliser assessment of an elderly patient. The overlap between bronchial phylline with agonists has been reported to increase myocardial damage in some animal asthma and COPD is less easy to define in the elderly and the proven efficacy of antistudies 12 and the hypokalaemic effects of nebulised agonists are increased in patients re-cholinergic bronchodilators in COPD would further justify their use. There is no evidence ceiving oral theophylline. 13 A further complication of treatment with to support a trial of anticholinergic drugs before agonists or vice versa, and both should always high dose agonists is hypoxaemia which may be responsible for increasing asthma mor-be tried. tality.
14 In a group of patients with asthma and COPD, 15 some of whom were hypoxic and hypercapnoeic, no serious fall in oxygen levels Assessment (P 2 ) occurred when patients received sal-The lack of published data in the elderly will butamol for 15 minutes from a nebuliser driven necessitate a degree of pragmatism in deciding by air. A proportion of patients who were hy-who should be issued with a nebuliser. Our percapnoeic developed further rises in carbon preference is to measure FEV 1 and FVC in dioxide (P 2 ) when the nebuliser was driven the laboratory after bronchodilators have been by oxygen. All patients returned to their pre-given by metered dose inhaler and nebuliser nebuliser (baseline) blood gas levels shortly on separate occasions. This is followed by a four after drug administration. In a similar study in week assessment period when peak expiratory an older group of 22 subjects 16 with severe flow rate is measured four times a day. The COPD (mean FEV 1 0.54-0.87 l) nebulised patient uses high dose inhaled bronchodilators terbutaline (4 mg) driven by air caused a rise with an inhaler device for the first two weeks, in P 2 even in those patients who were hypoxic. and a nebuliser for the second two. Peak flow Transcutaneous P 2 fell in the normoxic and recordings and symptoms are then discussed hypoxic group and the changes in oxygen sat-with the patient before it is decided whether to uration were attributed to mouthpiece induced supply him or her with a nebuliser. hyperventilation. The conclusion from both There is increasing evidence that the these studies was that nebulisers could be bronchodilator response to anticholinergic driven by air.
agents is less age dependent than the response to agonists [21] [22] [23] [24] and, on this evidence, we always recommend a combination of a agonist Anticholinergic drugs and ipratropium bromide in our elderly Ipratropium bromide and oxitropium bromide patients. have a good safety profile. There are no long
In conclusion, nebuliser treatment for the term studies of ipratropium in the elderly, but elderly needs further evaluation and should be short term studies in normal subjects and reserved for those patients who are symppatients with normal angle glaucoma have tomatic despite treatment with conventional shown that intraocular pressure, pupil dia-metered dose inhalers or dry powder inhalers meter, and accommodation are not affected by which they are using ineffectively but to the best ipratropium bromide given in doses up to four of their ability. After first checking potassium times that which is recommended. 17 Prolonged levels the patient should be given a nebuliser pupillary dilatation can occur if the drug is trial for at least two weeks. It is our clinical sprayed directly into the eye, and particular practice to assess peak flow and symptoms care needs to be taken if the drug is given before prescribing nebulisers and we routinely through a nebuliser when the face mask needs use combined agonist and anticholinergic to fit well. An alternative is to use the nebuliser therapy. with a mouthpiece attached to a T piece. 18 19 The potential risks of cardiac side effects of There is no evidence that inhaled ipratropium high dose inhaled agonists need to be evalugiven in the short term has any effect on urinary ated in well controlled clinical trials. flow in men aged 50-70, 20 but long term data on high dose nebulised ipratropium is required.
